<DOC>
	<DOCNO>NCT00884546</DOCNO>
	<brief_summary>To evaluate safety , tolerability , pharmacokinetics , pharmacodynamics BMS-833923 administer alone , combination lenalidomide plus dexamethasone , combination bortezomib subject relapse refractory multiple myeloma .</brief_summary>
	<brief_title>Multiple Ascending Dose ( MAD ) Combination Subjects With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Confirmed diagnosis Multiple Myeloma Men Women least 18 year old ECOG status 02 Last therapeutic diagnostic treatment least 21 day prior Bone marrow transplant must complete least 3 month prior Any toxicity prior therapy must resolve Grade â‰¤1 Women pregnant breastfeeding WOCBP unwilling/unable use acceptable method avoid pregnancy Uncontrolled medical disorder active infection Current recent ( w/in 3 month ) gastrointestinal disorder Inability swallow oral medication Inability venipunctured Uncontrolled significant cardiovascular disease Uncontrolled hyperlipidemia Intolerance lenalidomide bortezomib participate Arms B C Concurrent therapy investigational product Subjects involuntary incarcerate Subjects detain treatment psychiatric physical illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>